Evidence map›Paper›PMID 35184254›Full record

ArticleOphthalmology and therapy2022

Short-Term Effects of Atropine 0.01% on the Structure and Vasculature of the Choroid and Retina in Myopic Chinese Children.

Yuliang Wang, Xingxue Zhu, Yi Xuan, Min Wang, Xingtao Zhou, Xiaomei Qu

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06265454 (Effect of Low Concentration Atropine Eye Drops on Choroidal Thickness, Central Corneal Thickness, Anterior Scleral Thickness and Axial Length in Myopic Children), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06265454 phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

Effect of Low Concentration Atropine Eye Drops on Choroidal Thickness, Central Corneal Thickness, Anterior Scleral Thickness and Axial Length in Myopic Children

TypeinterventionalSponsorAin Shams UniversityRan2024 to 2026Enrolled75ConditionsMyopia Progression, Axial Length, Eye, Sclera ThicknessArmslow dose atropine eye drops, Placebo
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Atropine: Updates on myopia pharmacotherapy.Taiwan journal of ophthalmology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yuliang Wang *Department of Ophthalmology and Vision Science, Eye & ENT Hospital, Fudan University, Shanghai, China.
Xingxue Zhu *Department of Ophthalmology and Vision Science, Eye & ENT Hospital, Fudan University, Shanghai, China.
Yi XuanDepartment of Ophthalmology and Vision Science, Eye & ENT Hospital, Fudan University, Shanghai, China.
Min WangDepartment of Ophthalmology and Vision Science, Eye & ENT Hospital, Fudan University, Shanghai, China.
Xingtao ZhouDepartment of Ophthalmology and Vision Science, Eye & ENT Hospital, Fudan University, Shanghai, China.
Xiaomei QuDepartment of Ophthalmology and Vision Science, Eye & ENT Hospital, Fudan University, Shanghai, China. quxiaomei2002@126.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNEye & ENT Hospital of Fudan University · CNFudan University · CN

Funding

National Natural Science Foundation of China 82171093Shanghai Scientific Research Plan Project 21dz2311300
6 · The paper itself

Abstract

introductionTo explore the short-term effects of atropine 0.01% on the structure and vasculature of the choroid and retina in myopic Chinese children.

methodsThis study was a single-center randomized clinical trial. A total of 40 subjects with myopia < - 6.0 D were enrolled and randomized to receive atropine 0.01% once nightly with regular single-vision lenses or to simply wear regular single-vision lenses at an allocation ratio of 1:1. Follow-up visits were planned at 1 month and 3 months. Choroidal thickness (ChT) was obtained by optical coherence tomography (OCT). Retinal vessel density (RVD), retinal thickness (RT), foveal avascular zone (FAZ) and choriocapillaris flow (CCF) were measured by optical coherence tomography angiography (OCTA). The RVD and RT were measured at fovea, parafovea and perifovea area and four quadrants.

resultsTwenty-one subjects were allocated into the atropine group and 19 subjects into the control group. Over 3 months, the control group showed greater progression of myopia than those in the atropine group. ChT in the atropine group increased 11.12 ± 13.96 μm, which was not significant compared with that of the control group. None of the retinal sectors in atropine-treated eyes showed significant changes of RT and RVD compared with the control group. Besides, FAZ and CCF of the atropine group were not affected by atropine use over time, and there was no difference between the two groups.

conclusionAdministration of atropine 0.01% eye drops demonstrated no effect on RVD, FAZ and CCF over 3 months, while a modest increase of ChT was observed in atropine-treated eyes. TRIAL REGISTRATION NUMBER: ChiCTR1800017154.

Indexed as

AtropineChoroidMyopiaRetinaVasculature

Identifiers

PMID35184254
PMCPMC8927555
OpenAlexW4212820813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.